MetaVia Inc.: Results of Operations and Financial Condition (MTVA)

Nov 13, 2026, 8:38 AM ETResultsRead the original at SEC EDGAR

Good for MTVA

MetaVia's interim DA-1726 results showed lower liver fat and weight in an early study, supporting its drug program. The findings are not complete, with full Phase 1 data expected in Q1 2027.

MTVA · MetaVia Inc.

AI read · Good for MTVA

The AI's read

These findings give MetaVia a reason to advance DA-1726 toward testing in people with MetALD and ALD. The company plans a 48-week study of up to 150 people, starting in the second half of 2027. The findings are still interim. Complete Phase 1 data are expected in Q1 2027.

Get alerts for MTVA

Follow MetaVia Inc. (MTVA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MTVA

Free on the App Store and Google Play, or on the web.